艾托格列净联合二甲双胍治疗肥胖型2型糖尿病患者的效果

Effects of Ertugliflozin combined with Metformin in treatment of patients with obese type 2 diabetes

目的:观察艾托格列净联合二甲双胍治疗肥胖型2型糖尿病患者的效果。方法:回顾性分析2020年6月至2023年8月该院收治的82例肥胖型2型糖尿病患者的临床资料。根据治疗方案不同将其分为对照组与观察组各41例。对照组采用盐酸二甲双胍片治疗,观察组在对照组的基础上联合艾托格列净片治疗。比较两组临床疗效,治疗前后血糖指标[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]、血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、胰岛功能指标[空腹胰岛素(FINS)、胰岛β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)]水平,以及不良反应发生率。结果:观察组治疗总有效率为97.56%(40/41),高于对照组的80.49%(33/41),差异有统计学意义(P<0.05);治疗后,两组FPG、HbA1c、2hPG、FINS水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,观察组FPG、HbA1c、2hPG、FINS、HOMA-IR、TC、TG、LDL-C水平均低于对照组,HOMA-β、HDL-C水平均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:艾托格列净联合二甲双胍治疗肥胖型2型糖尿病患者效果显著,可降低血糖指标水平,调节血脂指标水平,改善胰岛功能,效果优于单用二甲双胍治疗。

Objective:To observe effects of Ertugliflozin combined with Metformin in treatment of patients with obese type 2 diabetes.Methods:The clinical data of 82 patients with obese type 2 diabetes admitted to this hospital from June 2020 to August 2023 were retrospectively analyzed.According to different treatment plans,they were divided into control group and observation group,41 cases in each group.The control group was treated with Metformin hydrochloride tablets,while the observation group was treated with Ertugliflozin tablets on the basis of that of the control group.The clinical efficacy,the levels of blood glucose indexes[fasting blood glucose(FPG),2 h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)],the blood lipid indexes[total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C)],the islet function indexes[fasting insulin(FINS),isletβcell function index(HOMA-β),insulin resistance index(HOMA-IR)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 97.56%(40/41),which was higher than 80.49%(33/41)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FPG,HbA1c,2hPG and FINS in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of FPG,HbA1c,2hPG,FINS,HOMA-IR,TC,TG and LDL-C in the observation group were lower than those in the control group,the levels of HOMA-βand HDL-C were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ertugliflozin combined with Metformin is effective in the treatment of obese type 2 diabetes,which can reduce the levels of blood glucose indexes,regulate the levels of blood lipid indexes and improve the islet function.Moreover,it is superior to simple Metformin treatment.